Home > Dermatology > AAD 2020 > A new topical PDE-4 inhibitor effective in psoriasis

A new topical PDE-4 inhibitor effective in psoriasis

Almost a third of patients with chronic plaque psoriasis achieved complete skin clearance with a roflumilast cream. In addition, difficult-to-treat intertriginous lesions and burden of disease were significantly reduced [1].

Apart from highly potent corticosteroids, the main topical treatment options in psoriasis consist of vitamin D analogues and retinoids. These drugs are not always well tolerated due to their side effects, especially over longer periods of time. “Specifically, we are worried about using corticosteroids or non- corticosteroids in facial and intertriginous areas because of irritation and other side effects like formation of stretch marks,” stressed Prof. Mark Lebwohl (Icahn School of Medicine at Mount Sinai, USA). The new topical treatment roflumilast inhibits phosphodiesterase (PDE)-4, which is known to be elevated in psoriatic skin lesions, thus influencing different cytokines like TNFα, IFNγ, IL-17, and IL-23.

The current phase ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on